38,461 Shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Acquired by AlphaMark Advisors LLC

AlphaMark Advisors LLC acquired a new position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 38,461 shares of the biopharmaceutical company’s stock, valued at approximately $73,000.

Other institutional investors also recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV raised its stake in shares of Akebia Therapeutics by 40.7% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,221 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 9,037 shares during the last quarter. Empirical Asset Management LLC acquired a new position in Akebia Therapeutics during the third quarter worth about $44,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Akebia Therapeutics in the second quarter valued at about $44,000. XTX Topco Ltd acquired a new stake in shares of Akebia Therapeutics in the third quarter valued at approximately $58,000. Finally, Intech Investment Management LLC purchased a new position in shares of Akebia Therapeutics during the 3rd quarter worth approximately $59,000. 33.92% of the stock is currently owned by hedge funds and other institutional investors.

Akebia Therapeutics Stock Performance

Shares of AKBA opened at $2.38 on Monday. Akebia Therapeutics, Inc. has a fifty-two week low of $0.80 and a fifty-two week high of $2.48. The company has a market capitalization of $519.27 million, a PE ratio of -10.35 and a beta of 0.72. The stock has a fifty day moving average of $1.95 and a two-hundred day moving average of $1.63.

Akebia Therapeutics (NASDAQ:AKBA) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The company had revenue of $37.43 million during the quarter, compared to analysts’ expectations of $45.66 million. During the same period in the prior year, the firm earned ($0.08) EPS. As a group, equities research analysts forecast that Akebia Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

AKBA has been the topic of a number of recent research reports. StockNews.com lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. HC Wainwright reaffirmed a “buy” rating and set a $7.50 price objective on shares of Akebia Therapeutics in a research note on Thursday.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.